The aim of this study was to evaluate the implication DNA methylation has in trastuzumab resistance and to identify epigenetically regulated genes with potential clinical value as biomarkers for trastuzumab resistance in HER2+ BC patients. Here, ERBB2 is linked to breast cancer.